Follicular Lymphoma Clinical Trials

A listing of 56 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

1 - 12 of 56

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 56 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Autism participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Healthy Volunteer Trials

Recruiting

Healthy volunteer trials near you are looking for participants to help push medical research forward. Click through to learn more!

Conditions:

Healthy

Healthy Volunteers

Learn More

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

NCT06131801

Recruiting

The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More

Gender:

All

Ages:

Between 0 years and 38 years

Trial Updated:

01/24/2024

Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma

Learn More ›

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Recruiting

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Gender:

All

Ages:

60 years and below

Trial Updated:

04/15/2024

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes

Learn More ›

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT06004167

Recruiting

Participants are invited to take part in this research study because they have relapsed (cancer has come back) or refractory (cancer has not responded to treatment) B-cell Lymphoma and will be undergoing CAR T-cell Therapy. This research is being done to see if a new radiation therapy administration schedule will positively impact the logistics, time, cost, and side effects of radiation therapy. In this research study, participants will receive radiation therapy once weekly for 5 weeks. This i... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/12/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations

Conditions: Lymphoma, B-Cell, Relapsed Cancer, Refractory Lymphoma, Diffuse Large B Cell Lymphoma, Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma

Learn More ›

Clonal Evolution in Follicular Lymphoma

NCT03190928

Recruiting

Background: Follicular lymphoma is a type of cancer of the lymph nodes. Lab studies are important for cancer research. They help scientists better understand differences in the cancer biology of different patients. Researchers want to collect serial samples over time from people with follicular lymphoma to help them design future treatments. Objective: To collect a variety of samples from people with follicular lymphoma to study how these diseases progress and respond to treatment. Eligibili... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/12/2024

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Follicular Lymphoma

Learn More ›

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417

Recruiting

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: Find the recommended dose of IMT-009 that can be safely given to participants Learn more about the side effects of IMT-009 Learn more about pharmacokinetics of IMT-009 Learn more about the effectiveness of IMT-009 Learn more about different pharmacokinetic b... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/09/2024

Locations: Site 9618, Tucson, Arizona +9 locations

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer, Esophageal Cancer, Colorectal Cancer, Diffuse Large B Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Follicular Lymphoma

Learn More ›

P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

NCT06014762

Recruiting

Phase 1 study comprised of open-label, dose escalation and expansion cohort study of P-CD19CD20-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed/refractory B cell malignancies

Gender:

All

Ages:

18 years and above

Trial Updated:

04/05/2024

Locations: University of California San Diego, La Jolla, California +9 locations

Conditions: Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Chronic Lymphocytic Leukemia

Learn More ›

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596

Recruiting

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: Glofitamab (a type of immunotherapy) Obinutuzumab (a type of immunotherapy)

Gender:

All

Ages:

18 years and above

Trial Updated:

04/05/2024

Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +1 locations

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. Cohort A: Participants with relapsed or refractory MCL rel... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/04/2024

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +100 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008, Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics (, Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), São Paulo, Sao Paulo

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 (, Rio de Janeiro, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0, London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena, Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron, Bologna, Emilia-Romagna

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Lazio

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant, Alessandria, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital- Isehara Campus ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital- Osakasayama Campus ( Site 1102), Osaka-sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

Japanese Foundation for Cancer Research ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Sit, Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

2CA BRAGA ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Not set

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( S, Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, England

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019

Recruiting

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose (RD) of SGR-1505.

Gender:

All

Ages:

18 years and above

Trial Updated:

04/03/2024

Locations: Banner Health - MD Anderson Cancer Center, Gilbert, Arizona +14 locations

Conditions: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma

Learn More ›

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

NCT04663347

Recruiting

A phase 1b/2, open-label, multinational, interventional trial to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics/biomarkers, immunogenicity, and preliminary efficacy of epcoritamab (EPKINLY™) in combination with other standard of care (SOC) agents in participants with B-cell Non-Hodgkin Lymphoma (B-NHL). The trial consists of 10 different treatment arms. Arm 9 (follicular lymphoma (FL)) is still open for enrolment of new patients, while the other arms have closed thei... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/02/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +63 locations

University of Alabama at Birmingham, Birmingham, Alabama

Cedars-Sinai Medical Center, Los Angeles, California

David Geffen School of Medicine at UCLA, Los Angeles, California

University of California San Francisco, San Francisco, California

Dana Farber Cancer Institute, Boston, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

John Theurer Cancer Center at Hackensack UMC, Hackensack, New Jersey

Mount Sinai, New York, New York

Memorial Sloan Kettering CC, New York, New York

Levine Cancer Center, Charlotte, North Carolina

UMPC Hillman Cancer Center Cancer Pavillion, Pittsburgh, Pennsylvania

UT Southwestern Medical Center, Dallas, Texas

Monash Medical Centre, Clayton, Victoria

Austin Health, Heidelberg, Not set

Linear Clinical Research Limited, Nedlands, Not set

AZ Sint-Jan, Brugge, Not set

Universitair Ziekenhuis Gent, Gent, Not set

CHU UCL Namur Site Godinne, Yvoir, Not set

Fakultni nemocnice Hradec Kralove, Hradec Králové, Not set

Fakultni nemocnice Ostrava, Ostrava - Poruba, Not set

Fakultni nemocnice v Motole, Prague, Not set

Vseobecna Fakultni Nemocnice, Praha 2, Not set

Århus Hospital, Arhus, Not set

Rigshospitalet, Copenhagen, Not set

Odense University Hospital, Odense, Not set

Vejle Sygehus, Vejle, Not set

Tampere University Hospital, Helsinki, Not set

Kuopio University Hospital, Kuopio, Not set

HUS Cancer Center, Lahti, Not set

Institut Bergonié, Bordeaux, Not set

CHU Dijon - Hopital du Bocage, Dijon, Not set

Hopital Claude Huriez - CHRU Lille, Lille, Not set

Hôpital de la Timone, Marseille, Not set

Hôpital Saint-Louis, Paris, Not set

Centre Hospitalier Lyon Sud, Pierre-Bénite, Not set

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Not set

Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS, Bologna, Not set

Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS, Candiolo, Not set

Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Not set

Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milan, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Not set

Amsterdam UMC, Locatie VUMC, Amsterdam, Not set

Universitair Medisch Centrum Groningen (UMCG), Groningen, Not set

Leids Universitair Medisch Centrum, Leiden, Not set

Maastricht University Medical Center, Maastricht, Not set

Erasmus Medisch Centrum, Rotterdam, Not set

UMC Utrecht, Utrecht, Not set

Oslo Universitetssykehus HF, Radiumhospitalet, Oslo, Not set

ICO l Hospitalet, Barcelona, Not set

Hospital Universitari Vall d'Hebron, Barcelona, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Södra Älvsborgs Sjukhus, Borås, Not set

Sahlgrenska Sjukhuset, Göteborg, Not set

Skånes Universitetssjukhus, Lund, Not set

Karolinska Universitetssjukhuset, Solna, Not set

Norrlands Universitetssjukhus, Umeå, Not set

Akademiska Sjukhuset, Uppsala, Not set

University College London Hospitals, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

Freeman Hospital, Newcastle Upon Tyne, Not set

Derriford Hospital, Plymouth, Not set

Conditions: Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

Learn More ›

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716

Recruiting

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Gender:

All

Ages:

18 years and above

Trial Updated:

04/01/2024

Locations: University of Alabama At Birmingham Hospital, Birmingham, Alabama +57 locations

University of Alabama At Birmingham Hospital, Birmingham, Alabama

Mayo Clinic Phoenix, Phoenix, Arizona

University of Arizona Cancer Center, Tucson, Arizona

University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California

Valkyrie Clinical Trials, Los Angeles, California

UCLA Santa Monica Cancer Care, Santa Monica, California

Stanford Medicine, Stanford, California

Uchealth North, Fort Collins, Colorado

Mayo Clinic Jacksonville, Jacksonville, Florida

Tampa General Hospital Cancer Institute, Tampa, Florida

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Norton Cancer Institute Pavilion, Louisville, Kentucky

Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana

American Oncology Partners of Maryland Pa, Bethesda, Maryland

Dana Farber Cancer Institute, Boston, Massachusetts

Mayo Clinic Rochester, Rochester, Minnesota

Nebraska Cancer Specialists, Grand Island, Nebraska

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Weill Cornell Medical College Newyork Presbyterian Hospital, New York, New York

Columbia University Medical Center, New York, New York

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Md Anderson Cancer Center, Houston, Texas

Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Concord Repatriation General Hospital, Concord, New South Wales

St Vincents Hospital Melbourne, Fitzroy, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Linear Clinical Research, Nedlands, Western Australia

Perth Blood Institute, West Perth, Western Australia

Tom Baker Cancer Center, Calgary, Alberta

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Hopital Estaing, Clermont Ferrand, Not set

Chu Henri Mondor, Creteil, Not set

Institut Paoli Calmettes, Marseille, Not set

Chu Montpellier Hopital Saint Eloi, Montpellier Cedex, Not set

Hopital de La Pitie Salpetriere, Paris, Not set

Centre Henri Becquerel, Rouen Cedex, Not set

Arensia Exploratory Medicine Llc, Tbilisi, Not set

Universitaetsklinikum Ulm, Innere Medizin Iii, Ulm, Not set

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna, Not set

Ospedale San Raffaele, Milano, Not set

Niguarda Cancer Center Division of Hematology, Milano, Not set

Centroricerche Cliniche Di Verona Srl, Verona, Not set

Inje University Busan Paik Hospital, Busan, Busan Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Hospital de La Santa Creu I Sant Pau, Barcelona, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital General Universitario Gregorio Maranon, Madrid, Not set

Md Anderson Cancer Center Madrid Spain, Madrid, Not set

Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Sahlgrenska University Hospital Hematology, Goteborg, Not set

Karolinska Universitetssjukhuset Solna, Stockholm, Not set

Uppsala Akademiska Sjukhus, Uppsala, Not set

Conditions: B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-hodgkin Lymphoma, Waldenström Macroglobulinemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

Learn More ›

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696

Recruiting

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.

Gender:

All

Ages:

Between 3 years and 39 years

Trial Updated:

04/01/2024

Locations: University of Colorado, Aurora, Colorado +5 locations

Conditions: Hematologic Diseases, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease, Acute Leukemia in Remission

Learn More ›

1 - 12 of 56